GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Rain Oncology Inc (NAS:RAIN) » Definitions » Total Current Liabilities

Rain Oncology (Rain Oncology) Total Current Liabilities : $14.48 Mil (As of Sep. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Rain Oncology Total Current Liabilities?

Total current liabilities includes Accounts Payable & Accrued Expense, Short-Term Debt & Capital Lease Obligation, Other Current Liabilities, and Current Deferred Liabilities. Rain Oncology's total current liabilities for the quarter that ended in Sep. 2023 was $14.48

Rain Oncology Total Current Liabilities Historical Data

The historical data trend for Rain Oncology's Total Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Rain Oncology Total Current Liabilities Chart

Rain Oncology Annual Data
Trend Dec19 Dec20 Dec21 Dec22
Total Current Liabilities
1.22 3.42 16.32 21.97

Rain Oncology Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Total Current Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 13.01 21.97 19.48 18.33 14.48

Rain Oncology Total Current Liabilities Calculation

Total Current Liabilities is the total amount of liabilities that the company needs to pay over the next 12 months.

Rain Oncology's Total Current Liabilities for the fiscal year that ended in Dec. 2022 is calculated as

Total Current Liabilities=Accounts Payable & Accrued Expense+Short-Term Debt & Capital Lease Obligation
=18.423+0.164
+Other Current Liabilities+Current Deferred Liabilities
=3.379+0
=21.97

Rain Oncology's Total Current Liabilities for the quarter that ended in Sep. 2023 is calculated as

Total Current Liabilities=Accounts Payable & Accrued Expense+Short-Term Debt & Capital Lease Obligation
=12.54+0.456
+Other Current Liabilities+Current Deferred Liabilities
=1.481+0
=14.48

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The increase of Total Current Liabilities of a company is not necessarily a bad thing. This may conserve the company's cash and contribute positively to cash flow.

Total Current Liabilities is linked to Total Current Assets through the Current Ratio and Working Capital. The Current Ratio is equal to dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations. Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

Be Aware

Stay away from companies that roll over the debt e.g. Bear Stearns

When investing in financial institutions, Buffett shies from those who are bigger borrowers of short term than long term debt.

His favorite Wells Fargo has 57 cents short term debt for every dollar of long term.

Aggressive banks (like Bank of America) has $2.09 short term for every dollar long term

Rain Oncology Total Current Liabilities Related Terms

Thank you for viewing the detailed overview of Rain Oncology's Total Current Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Rain Oncology (Rain Oncology) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Rain Oncology Inc (NAS:RAIN) » Definitions » Total Current Liabilities
Comparable Companies
LPTX ICCC CKPT DARE BYSI BSEM BOLT PRTG RZLT CELU OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA XBRU:ARGX HKSE:02269 BNTX
Traded in Other Exchanges
N/A
Address
8000 Jarvis Avenue, Suite 204, Newark, CA, USA, 94560
Website
https://www.rainoncology.com
Rain Oncology Inc is a late-stage precision oncology company developing therapies that target oncogenic drivers for which it is able to genetically select patients it believes will likely benefit. This approach includes using a tumor-agnostic approach to select patients based on their tumors' underlying genetics rather than histology. The company's product candidate, milademetan, is a small molecule, oral inhibitor of MDM2, which is oncogenic in numerous cancers. In addition to milademetan, the company is also developing a preclinical program that is focused on inducing synthetic lethality in cancer cells by inhibiting RAD52.
Executives
Kevin C Tang 10 percent owner 4747 EXECUTIVE DRIVE, SUITE 210, SAN DIEGO CA 92121
Josephine Bruce officer: Principal Fin. & Acc. Officer 8000 JARVIS AVENUE, SUITE 204, NEWARK CA 94560
Tang Capital Partners Lp 10 percent owner 4747 EXECUTIVE DRIVE, SUITE 210, SAN DIEGO CA 92121
Tang Capital Management Llc 10 percent owner 4747 EXECUTIVE DRIVE, SUITE 210, SAN DIEGO CA 92121
Boxer Capital, Llc other: See remarks. 12860 EL CAMINO REAL, SUITE 300, SAN DIEGO CA 92130
Boxer Asset Management Inc. other: See remarks CAY HOUSE, EP TAYLOR DRIVE N7776, LYFORD CAY, NEW PROVIDENCE C5 00000
Joseph Lewis other: See remarks. PO BOX N7776, LYFORD BAHAMAS
Aaron I. Davis director 12860 EL CAMINO REAL, SUITE 300, SAN DIEGO CA 92130
Erik Atkisson officer: General Counsel and CCO C/O EIGER BIOPHARMACEUTICALS, INC., 2155 PARK BLVD., PALO ALTO CA 94306
Franklin M Berger director 1000 MARINA BLVD, STE 200, BRISBANE CA 94005
Biotechnology Value Fund L P other: See Explanation of Responses 44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
Avanish Vellanki director, officer: President and CEO 8000 JARVIS AVENUE, SUITE 204, NEWARK CA 94560
Perceptive Life Sciences Master Fund Ltd 10 percent owner C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Cormorant Asset Management, Lp 10 percent owner 200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Gorjan Hrustanovic director C/O KYMERA THERAPEUTICS, INC., 200 ARSENAL YARDS, SUITE 230, WATERTOWN MA 02472

Rain Oncology (Rain Oncology) Headlines

From GuruFocus

ROSEN, A TOP RANKED LAW FIRM, Encourages Rain Oncology Inc. Investors to Secure Counsel Before Important September 12 Deadline in Securities Class Action - RAIN

By PRNewswire • 09-12-2023

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims�On Behalf of Investors of Rain Oncology Inc. - RAIN

By Marketwired • 09-01-2023

RAIN DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Rain Oncology, Inc. and Encourages Investors to Contact the Firm

By Business Wire • 09-09-2023

RAIN Investors Have Opportunity to Lead Rain Oncology Inc. Securities Fraud Lawsuit

By PRNewswire • 09-08-2023

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Rain Oncology Inc. - RAIN

By PRNewswire • 09-05-2023

SHAREHOLDER ALERT: Levi & Korsinsky Notifies Rain Oncology Inc.(RAIN) Investors of a Class Action Lawsuit and Upcoming Deadline

By PRNewswire • 09-07-2023

SHAREHOLDER ALERT: Levi &�Korsinsky Notifies Rain Oncology Inc. (RAIN)�Investors of a Class Action Lawsuit and Upcoming Deadline

By Marketwired • 09-11-2023

SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Rain Oncology Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of September 12, 2023 - (NASDAQ: RAIN)

By PRNewswire • 09-12-2023

Rain Oncology Confirms Receipt of Unsolicited Proposal from Concentra Biosciences

By Marketwired • 10-16-2023

Shareholder Alert: Ademi LLP investigates whether Rain Oncology Inc. has obtained a Fair Price in its transaction with Pathos

By PRNewswire • 12-14-2023